GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) Director Keith Meister purchased 46,273 shares of the firm’s stock in a transaction on Friday, May 15th. The shares were acquired at an average price of $38.91 per share, with a total value of $1,800,482.43. Following the purchase, the director directly owned 4,784,570 shares in the company, valued at $186,167,618.70. This represents a 0.98% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
GeneDx Stock Up 4.9%
WGS stock traded up $1.90 during midday trading on Friday, reaching $40.75. 1,621,837 shares of the company’s stock traded hands, compared to its average volume of 997,857. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -15.21 and a beta of 2.06. The firm’s fifty day moving average price is $64.78 and its 200-day moving average price is $102.43. The company has a quick ratio of 2.95, a current ratio of 3.09 and a debt-to-equity ratio of 0.38. GeneDx Holdings Corp. has a 52 week low of $32.21 and a 52 week high of $170.87.
GeneDx (NASDAQ:WGS – Get Free Report) last announced its quarterly earnings results on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). The business had revenue of $102.25 million for the quarter, compared to the consensus estimate of $112.46 million. GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. During the same quarter last year, the firm posted ($0.23) EPS. As a group, sell-side analysts forecast that GeneDx Holdings Corp. will post -1 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Check Out Our Latest Stock Report on WGS
Hedge Funds Weigh In On GeneDx
Several institutional investors have recently modified their holdings of the business. Arizona State Retirement System grew its holdings in shares of GeneDx by 2.1% in the fourth quarter. Arizona State Retirement System now owns 5,594 shares of the company’s stock valued at $728,000 after acquiring an additional 113 shares in the last quarter. Cerity Partners LLC grew its holdings in shares of GeneDx by 6.0% in the fourth quarter. Cerity Partners LLC now owns 2,527 shares of the company’s stock valued at $329,000 after acquiring an additional 142 shares in the last quarter. Main Management ETF Advisors LLC grew its holdings in shares of GeneDx by 1.0% in the fourth quarter. Main Management ETF Advisors LLC now owns 15,660 shares of the company’s stock valued at $2,037,000 after acquiring an additional 160 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of GeneDx by 5.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,702 shares of the company’s stock valued at $399,000 after acquiring an additional 181 shares in the last quarter. Finally, Jones Financial Companies Lllp grew its holdings in shares of GeneDx by 664.3% in the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock valued at $25,000 after acquiring an additional 186 shares in the last quarter. 61.72% of the stock is owned by institutional investors.
About GeneDx
GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.
Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.
See Also
- Five stocks we like better than GeneDx
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.
